Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-928-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Chiasma (NASDAQ:CHMA) Frequently Asked Questions
What is Chiasma's stock symbol?
Chiasma trades on the NASDAQ under the ticker symbol "CHMA."
How were Chiasma's earnings last quarter?
Chiasma Inc (NASDAQ:CHMA) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.04. View Chiasma's Earnings History.
When is Chiasma's next earnings date?
What price target have analysts set for CHMA?
5 analysts have issued 12 month price targets for Chiasma's shares. Their forecasts range from $11.00 to $18.00. On average, they anticipate Chiasma's share price to reach $14.00 in the next year. This suggests a possible upside of 164.2% from the stock's current price. View Analyst Price Targets for Chiasma.
What is the consensus analysts' recommendation for Chiasma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.
What are Wall Street analysts saying about Chiasma stock?
Here are some recent quotes from research analysts about Chiasma stock:
- 1. According to Zacks Investment Research, "Chiasma, Inc. is a biopharmaceutical company. The company's TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. " (8/16/2019)
- 2. HC Wainwright analysts commented, "Our $11 price target is based on our DCF valuation. Our DCF model utilizes a terminal rate of decline of 10%, and a WACC-based discount rate of 10.0% (Beta of 1.0, equity risk premium of 5.6%). We assume a 21% tax rate. We apply an 80% risk adjustment to our valuation to account for probability of success for the U.S. and European trials. We currently apply a negative terminal growth rate to account for potential launches by competitors. However, our valuation does not include potential new applications of Chiasma’s TPE platform technology." (7/23/2019)
Has Chiasma been receiving favorable news coverage?
Media stories about CHMA stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chiasma earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Chiasma.
Are investors shorting Chiasma?
Chiasma saw a increase in short interest during the month of July. As of July 15th, there was short interest totalling 646,000 shares, an increase of 134.7% from the June 15th total of 275,300 shares. Based on an average trading volume of 596,400 shares, the short-interest ratio is currently 1.1 days. Approximately 4.8% of the shares of the company are sold short. View Chiasma's Current Options Chain.
Who are some of Chiasma's key competitors?
Some companies that are related to Chiasma include Axsome Therapeutics (AXSM), Cytokinetics (CYTK), ZIOPHARM Oncology (ZIOP), ANI Pharmaceuticals (ANIP), Kura Oncology (KURA), Vanda Pharmaceuticals (VNDA), Alder Biopharmaceuticals (ALDR), Arvinas (ARVN), Eagle Pharmaceuticals (EGRX), OrganiGram (OGI), CannTrust (CNTTF), Retrophin (RTRX), Akero Therapeutics (AKRO), MacroGenics (MGNX) and Homology Medicines (FIXX).
What other stocks do shareholders of Chiasma own?
Who are Chiasma's key executives?
Chiasma's management team includes the folowing people:
- Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 56)
- Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 45)
- Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 54)
- Dr. Gary Patou, Head of Clinical (Age 60)
When did Chiasma IPO?
(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.
Who are Chiasma's major shareholders?
Chiasma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (7.48%), BlackRock Inc. (5.04%), Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (1.30%), Fosun International Ltd (0.39%) and Altshuler Shaham Ltd (0.32%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View Institutional Ownership Trends for Chiasma.
Which major investors are selling Chiasma stock?
Which major investors are buying Chiasma stock?
CHMA stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Vanguard Group Inc., Renaissance Technologies LLC, Fosun International Ltd, Strs Ohio, Bank of New York Mellon Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick and William Ludlam. View Insider Buying and Selling for Chiasma.
How do I buy shares of Chiasma?
Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chiasma's stock price today?
One share of CHMA stock can currently be purchased for approximately $5.30.
How big of a company is Chiasma?
Chiasma has a market capitalization of $221.49 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.
What is Chiasma's official website?
How can I contact Chiasma?
Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]
MarketBeat Community Rating for Chiasma (NASDAQ CHMA)
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
